Bristol-Myers Squibb (BMY) Shares Sold by Goelzer Investment Management Inc.

Goelzer Investment Management Inc. cut its stake in Bristol-Myers Squibb (NYSE:BMY) by 57.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 32,976 shares of the biopharmaceutical company’s stock after selling 44,371 shares during the period. Goelzer Investment Management Inc.’s holdings in Bristol-Myers Squibb were worth $2,086,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of BMY. BlackRock Inc. increased its stake in shares of Bristol-Myers Squibb by 5.0% during the 4th quarter. BlackRock Inc. now owns 104,293,294 shares of the biopharmaceutical company’s stock worth $6,391,093,000 after purchasing an additional 4,945,515 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Bristol-Myers Squibb by 31.9% during the 4th quarter. Renaissance Technologies LLC now owns 14,302,900 shares of the biopharmaceutical company’s stock worth $876,482,000 after purchasing an additional 3,456,300 shares in the last quarter. TIAA CREF Investment Management LLC increased its stake in shares of Bristol-Myers Squibb by 30.8% during the 4th quarter. TIAA CREF Investment Management LLC now owns 10,932,722 shares of the biopharmaceutical company’s stock worth $669,957,000 after purchasing an additional 2,573,967 shares in the last quarter. Orbis Allan Gray Ltd increased its stake in shares of Bristol-Myers Squibb by 31.1% during the 4th quarter. Orbis Allan Gray Ltd now owns 6,901,670 shares of the biopharmaceutical company’s stock worth $422,935,000 after purchasing an additional 1,635,666 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. increased its stake in shares of Bristol-Myers Squibb by 109.0% during the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 2,797,167 shares of the biopharmaceutical company’s stock worth $171,409,000 after purchasing an additional 1,458,723 shares in the last quarter. 71.49% of the stock is owned by institutional investors.

BMY has been the subject of a number of recent research reports. Morgan Stanley raised shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $51.56 to $78.00 in a research note on Thursday, February 15th. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Monday, January 29th. Vetr cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price objective for the company. in a research note on Tuesday, January 16th. Jefferies Group set a $70.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Friday, March 23rd. Finally, BMO Capital Markets reissued a “sell” rating and set a $52.00 price objective on shares of Bristol-Myers Squibb in a research note on Monday, January 22nd. Three research analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $63.68.



In related news, Director Dinesh C. Paliwal purchased 4,770 shares of the firm’s stock in a transaction on Monday, April 30th. The shares were bought at an average price of $52.40 per share, for a total transaction of $249,948.00. Following the acquisition, the director now directly owns 8,027 shares in the company, valued at $420,614.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.12% of the stock is currently owned by company insiders.

Shares of Bristol-Myers Squibb opened at $51.86 on Monday, according to MarketBeat.com. Bristol-Myers Squibb has a 1 year low of $49.96 and a 1 year high of $70.05. The company has a market cap of $84.77 billion, a P/E ratio of 16.67, a PEG ratio of 1.30 and a beta of 0.99. The company has a current ratio of 1.52, a quick ratio of 1.39 and a debt-to-equity ratio of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 26th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a net margin of 4.37% and a return on equity of 37.56%. The firm had revenue of $5.19 billion for the quarter, compared to analyst estimates of $5.25 billion. During the same quarter last year, the business earned $0.84 earnings per share. Bristol-Myers Squibb’s revenue was up 5.4% compared to the same quarter last year. sell-side analysts anticipate that Bristol-Myers Squibb will post 3.41 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, May 1st. Investors of record on Friday, April 6th were given a dividend of $0.40 per share. The ex-dividend date was Thursday, April 5th. This represents a $1.60 dividend on an annualized basis and a yield of 3.09%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 53.16%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply